For patients with refractory uveitis not responsive to anti-TNF drugs, other therapeutic approaches have been reported anecdotally, including checking for antidrug antibodies, weekly adalimumab abatacept, and JAK-kinase inhibitors.35, 36, 37 Tocilizumab might provide a valuable adjunctive therapeutic option for children with uveitis refractory to anti-TNF, particularly as adalimumab is the only evidence-based and licensed therapy. This evidence concerns the gene TNF and uveitis.